S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
Palantir Stock Has It all… Except the Analysts' Support
Critical asset just had biggest fall on record (Ad)
3 wealth-compounding stocks to beat the market this decade
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
2 Navigation Stocks That Continue to Defy Gravity
Workday Stock Price is Working on a Buy-the-Dip Opportunity
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Applied Optoelectronics earnings dumper, pain now for gain later?
NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Price, News & Analysis

$2.36
-0.26 (-9.92%)
(As of 02/28/2024 ET)
Today's Range
$2.35
$2.59
50-Day Range
$1.94
$3.33
52-Week Range
$1.43
$8.65
Volume
3.11 million shs
Average Volume
5.03 million shs
Market Capitalization
$262.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.22

Coherus BioSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
375.5% Upside
$11.22 Price Target
Short Interest
Healthy
22.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
1.13mentions of Coherus BioSciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.18) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

119th out of 958 stocks

Biological Products, Except Diagnostic Industry

14th out of 151 stocks


CHRS stock logo

About Coherus BioSciences Stock (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock Price History

CHRS Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Coherus BioSciences Inc (CHRS)
Coherus Biosciences Amends Loan Terms with Biopharma
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
CHRS Jan 2026 7.000 call
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
2/28/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
299
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$11.22
High Stock Price Target
$23.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+373.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-291,750,000.00
Net Margins
-102.86%
Pretax Margin
-103.04%

Debt

Sales & Book Value

Annual Sales
$211.04 million
Book Value
($1.77) per share

Miscellaneous

Free Float
99,125,000
Market Cap
$263.92 million
Optionable
Optionable
Beta
0.53

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 69)
    Chairman, President & CEO
    Comp: $1.79M
  • Mr. Bryan J. McMichael (Age 46)
    Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Ms. Jami Taylor
    Vice President of Investor Relations
  • Cheston Turbyfill
    Vice President of Communications
  • Mr. Scott Saywell
    Executive Vice President of Corporate Development
  • Ms. Rebecca Sunshine (Age 61)
    Chief Human Resources Officer
  • Mr. Michael Chen
    Senior Vice President of Commercial Analytics & Trade
  • Mr. Paul Reider (Age 55)
    Chief Commercial Officer
  • Dr. Theresa M. Lavallee Ph.D. (Age 58)
    Chief Development Officer & Chairman of Scientific Advisory Board














CHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price target for 2024?

7 Wall Street analysts have issued 1-year price objectives for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $23.00. On average, they predict the company's stock price to reach $11.22 in the next twelve months. This suggests a possible upside of 375.5% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2024?

Coherus BioSciences' stock was trading at $3.33 on January 1st, 2024. Since then, CHRS shares have decreased by 29.1% and is now trading at $2.36.
View the best growth stocks for 2024 here
.

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a drop in short interest in February. As of February 15th, there was short interest totaling 25,320,000 shares, a drop of 10.0% from the January 31st total of 28,130,000 shares. Based on an average daily volume of 5,930,000 shares, the days-to-cover ratio is presently 4.3 days.
View Coherus BioSciences' Short Interest
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Monday, March, 6th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.12. The biotechnology company earned $45.35 million during the quarter, compared to the consensus estimate of $45.72 million. During the same quarter last year, the firm posted ($0.60) earnings per share.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).

What guidance has Coherus BioSciences issued on next quarter's earnings?

Coherus BioSciences issued an update on its FY 2023 earnings guidance on Wednesday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $260.0 million-$260.0 million, compared to the consensus revenue estimate of $260.5 million.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.30%), Peregrine Capital Management LLC (0.98%), Charles Schwab Investment Management Inc. (0.69%), Nuveen Asset Management LLC (0.68%), Cubist Systematic Strategies LLC (0.35%) and Sei Investments Co. (0.33%). Insiders that own company stock include Dennis M Lanfear, James Healy, Mcdavid Stilwell and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
This page (NASDAQ:CHRS) was last updated on 2/29/2024 by MarketBeat.com Staff